References
- Jagadeesh K . Comparison of intrathecally administered fentanyl and midazolam in combination with hyberbaric bupivacaine . J. Evid. Based Med. Healthcare2 ( 24 ), 3587 – 3595 ( 2015 ).
- Gugsa NG . History pain and pain management . Res. Med. Eng. Sci.3 ( 4 ), 1 – 3 ( 2018 ).
- Andreu V , ArrueboM . Current progress and challenges of nanoparticle based therapeutics in pain management . J. Control. Release269 , 189 – 213 ( 2018 ).
- Treede R-D , RiefW , BarkeAet al. A classification of chronic pain for ICD-11 . Pain156 ( 6 ), 1003 – 1007 ( 2015 ).
- Fayaz A , CroftP , LangfordRM , DonaldsonLJ , JonesGT . Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies . BMJ Open6 , e010364 ( 2016 ).
- Tompkins AD , HobelmannG , ComptonP . Providing chronic pain management in the ‘Fifth Vital Sign’ era: historical and treatment perspectives on a modern-day medical dilemma . Drug Alcohol Depend.173 ( 1 ), S11 – S21 ( 2017 ).
- Joshi GM . Holistic care in chronic pain . Indian J. Pain31 , 77 – 79 ( 2017 ).
- Ussai S , MiceliL , PisaFEet al. Impact of potential inappropriate NSAIDs use in chronic pain . Drug Des. Devel. Ther.9 , 2073 – 2077 ( 2015 ).
- Crofford LJ . Use of NSAIDs in treating patients with arthritis . Arthritis Res. Ther.15 ( Suppl 3 ), 2 – 10 ( 2013 ).
- Yaksh TL , WallaceMS . Opioids, analgesia, and pain management . In : Goodman & Gilman’s The Pharmacological Basis of Therapeutics (12th Edition) . BruntonLL , ChabnerBA , KnollmannBC ( Eds ). McGraw-Hill , CA, USA , 81 – 527 ( 2011 ).
- Rosenblatt RA , CatlinM . Opioids for chronic pain: first do no harm . Ann. FAM Med.10 ( 4 ), 300 – 301 ( 2012 ).
- Goodman CW , BrettAS . Gabapentin and pregabalin for pain – is increased prescribing a cause for concern?N. Engl. J. Med.377 , 411 – 414 ( 2017 ).
- Patel R , DickensonAH . Mechanisms of the gabapentinoids and α2 δ-1 calcium channel subunit in neuropathic pain . Pharmacol. Res. Perspect.4 ( 2 ), e00205 ( 2016 ).
- Morrison EE , SandilandsEA , WebbDJ . Gabapentin and pregabalin: do the benefits outweigh the harms?J. R. Coll. Physicians Edinb.47 ( 4 ), 310 – 313 ( 2017 ).
- Wallach JD , RossJS . Gabapentin approvals, off-label use, and lessons for post-marketing evaluation efforts . JAMA319 ( 8 ), 776 – 778 ( 2018 ).
- Evoy KE , MorrisonMD , SakladSR . Abuse and misuse of pregabalin and gabapentin . Drugs77 ( 4 ), 403 – 426 ( 2017 ).
- Smith RV , HavensJR , WalshSL . Gabapentin misuse, abuse, and diversion: a systematic review . Addiction111 ( 7 ), 1160 – 1174 ( 2016 ).
- Gomes T , JuurlinkDN , AntoniouT , MamdaniMM , PatersonJM , van den BrinkW . Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case–control study . PLoS Med.14 ( 10 ), e1002396 ( 2017 ).